Search Results

filter by

diseases

news type

event type

topic type

location-search

date range filter – slider
1999 — 2025

DNDi 2025 Projects of the Year recognize contributions of DNDi teams and partners working to deliver urgently needed innovations for people affected by Chagas disease and river blindness

DNDi's 2025 Projects of the Year are Biomarkers for Chagas disease and emodepside for river blindness.
  • News

DNDi 2025 Projects of the Year recognize contributions of DNDi teams and partners working to deliver urgently needed innovations for people affected by Chagas disease and river blindness

DNDi's 2025 Projects of the Year are Biomarkers for Chagas disease and emodepside for river blindness.
  • News

New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial

BMJ Open

  • Scientific articles

New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial

  • Scientific articles

AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease

DNDi will share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease. Startup activities are underway for a Phase I first-in-human study for oral AN2-502998, with a Phase II study initiation planned for 2026.
  • Press releases
PaedsFilm2024-ValleduparColombia-202409-22

AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease

DNDi will share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease. Startup activities are underway for a Phase I first-in-human study for oral AN2-502998, with a Phase II study initiation planned for 2026.
  • Press releases
PaedsFilm2024-ValleduparColombia-202409-22

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

  • Press releases
Chagas-Colombia-RapidTests-202505-01

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

  • Press releases
Chagas-Colombia-RapidTests-202505-01

Please select a search term or criteria.

loading
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

Get in touch

Support us

Work with us